Home > Insider Trading > Filing (0001209191-18-049373)

Filing Details

Accession Number:: 0001209191-18-049373
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-09-04 19:39:21
Reporting Period:: 2018-08-30

Accepted Time:: 2018-09-04 19:39:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1619087	Steadymed Ltd.	STDY	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1636975	W. David Nassif	C/O Steadymed Therapeutics, Inc. 2603 Camino Ramon, Suite 350 San Ramon CA 94583	Evp And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2018-08-30	22,157	$4.46	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Option (Rt to Buy)	Disposition	2018-08-30	3,100	$0.00	3,100	$3.61
Ordinary Shares	Stock Option (Rt to Buy)	Disposition	2018-08-30	159,642	$0.00	159,642	$3.61
Ordinary Shares	Stock Option (Rt to Buy)	Disposition	2018-08-30	51,832	$0.00	51,832	$5.84
Ordinary Shares	Stock Option (Rt to Buy)	Disposition	2018-08-30	40,000	$0.00	20,000	$2.74
Ordinary Shares	Stock Option (Rt to Buy)	Disposition	2018-08-30	15,987	$0.00	15,987	$3.65

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2019-07-19	No	4	J	Direct
2020-05-01	No	4	J	Direct
2022-01-25	No	4	J	Direct
2026-06-17	No	4	J	Direct
2027-12-28	No	4	J	Direct

Footnotes

Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding restricted share unit was converted into the right to receive (1) a cash payment equal to (x) $4.46, multiplied by (y) the total number of shares subject to such restricted share unit and (2) a number of CVRs equal to the total number of shares subject to such restricted share unit.
Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.
Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.